Key Highlights

  • Second-quarter 2026 Revenue was about $18.6 million, largely from marketed drug Zynlonta (loncastuximab tesirine) for certain lymphomas.
  • The company narrowed its loss as spending fell, ending the period with a cash position reported around $219.1 million.
  • Reporting noted concerns weighing on the LOTIS-5 confirmatory trial, an important study tied to Zynlonta's broader use.
  • ADC Therapeutics specializes in antibody-drug conjugates, targeted therapies that deliver a toxic payload directly to cancer cells.

ADC Therapeutics (NYSE:ADCT) is working to build on its approved lymphoma treatment while advancing a pipeline of antibody-drug conjugates. The company reported second-quarter 2026 results that narrowed its loss, though questions around a key confirmatory study tempered the picture.

ADC Therapeutics combines a commercial product with a technology platform in a competitive field, and the interplay between its marketed drug, its pipeline and its cash position defines the Investment case.

Second-Quarter Results and a Regulatory Watch-Item

For the second quarter of 2026, ADC Therapeutics reported revenue of about $18.6 million, largely from its marketed drug Zynlonta (loncastuximab tesirine) for certain lymphomas, and it narrowed its loss as spending fell. The company ended the period with a cash position reported around $219.1 million, providing runway to advance its programs. However, reporting noted concerns weighing on the LOTIS-5 confirmatory trial, an important study tied to Zynlonta's broader use, reflecting the regulatory scrutiny that accompanies confirmatory requirements for accelerated approvals.

Business and Financial Position

ADC Therapeutics specializes in antibody-drug conjugates, targeted therapies that deliver a toxic payload directly to cancer cells, with Zynlonta as its lead commercial product in lymphoma and additional candidates in development. Its value rests on growing Zynlonta's use, including potential label expansions supported by trials like LOTIS-5, and on advancing its pipeline, all while managing cash in a competitive oncology market.

Zynlonta's Growth Hinges on the LOTIS-5 Outcome

The key signals are Zynlonta's sales trajectory and any label-expansion progress, the outcome and implications of the LOTIS-5 confirmatory trial, and pipeline milestones. Investors will be monitoring cash runway, expense discipline, and competition in lymphoma and the broader ADC field.

Antibody-drug conjugates have become one of oncology's most active areas, with large pharmaceutical companies investing heavily, which creates both validation and competition for ADC Therapeutics' platform. Zynlonta's performance and the resolution of the LOTIS-5 confirmatory-trial question will largely determine whether the company can grow its commercial base.